Literature DB >> 11192074

Value of inhibin staining in gynecological pathology.

W G McCluggage1.   

Abstract

Recent years have seen the publication of many articles investigating the value of antibodies against inhibin in diagnostic surgical pathology. This review concentrates on the uses of inhibin staining in gynecological pathology. alpha-inhibin is diagnostically the most useful antibody and is a sensitive immunohistochemical marker of most ovarian sex cord-stromal tumors and, as such, is of value in the diagnosis of this heterogeneous group of neoplasms that can be confused morphologically with a wide range of other tumors. Because the antibody is not entirely specific for ovarian sex cord-stromal tumors, it should always be used as part of a larger panel. alpha-inhibin staining may also be of value in confirming late recurrence or metastasis of an ovarian sex cord-stromal tumor, especially a granulosa cell tumor. Sex cord-like elements within uterine tumors resembling ovarian sex cord tumors are also commonly immunoreactive with alpha-inhibin, perhaps indicating true sex cord differentiation. alpha-inhibin staining may also be of value in cytological preparations in confirming a functional cyst and excluding a cyst or cystadenoma of epithelial origin. Syncytiotrophoblastic cells are also immunoreactive, as are most trophoblastic tumors. Thus, positive staining may be of value in confirming an intrauterine gestation or in the diagnosis of a trophoblastic neoplasm. Another gynecological neoplasm that is commonly positive with alpha-inhibin is the so-called female adnexal tumor of probable wolffian origin, and, therefore, the antibody is of no value in the distinction of this neoplasm from a sex cord-stromal tumor, tumors that are often in the differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11192074     DOI: 10.1097/00004347-200101000-00007

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  8 in total

1.  Retiform Sertoli-Leydig cell tumor of ovary in a 9-year-old girl: case report and review of the literature.

Authors:  Weizhen Lou; Dongyan Cao; Jiaxin Yang; Lina Guo; Keng Shen
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

2.  Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms.

Authors:  V I Shah; O N Freites; P Maxwell; W G McCluggage
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

3.  Cytologic features of sex cord-stromal tumors in women.

Authors:  Liz N Edmund; Abeer M Salama; Rajmohan Murali
Journal:  Cancer Cytopathol       Date:  2021-08-19       Impact factor: 4.264

4.  Follicular expression of c-Kit/SCF and inhibin-alpha in mouse ovary during development.

Authors:  Jae Seong Kang; Chang Joo Lee; Jong Min Lee; Joong Yeol Rha; Kang Won Song; Moon Hyang Park
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

5.  Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study.

Authors:  Hala M Abdul-Al; Hala R Makhlouf; Zachary D Goodman
Journal:  Virchows Arch       Date:  2007-04-25       Impact factor: 4.064

6.  Non-neoplastic granulosa cells within ovarian vascular channels: a rare potential diagnostic pitfall.

Authors:  W G McCluggage; R H Young
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

7.  [Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors].

Authors:  F Kommoss; D Schmidt
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

8.  Ovarian mucinous epithelial neoplasm showing immunohistochemical pattern of lower gastrointestinal origin with stromal minor sex-cord elements: A case report.

Authors:  Taeko Ueda; Hitomi Nakagawa; Toru Hachisuga
Journal:  Gynecol Oncol Rep       Date:  2014-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.